Targeted Therapies in Non-Small Cell Lung Cancer—Beyond EGFR and ALK
Systemic therapy for non-small cell lung cancer (NSCLC) has undergone a dramatic paradigm shift over the past decade. Advances in our understanding of the underlying biology of NSCLC have revealed distinct molecular subtypes. A substantial proportion of NSCLC depends on oncogenic molecular aberratio...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2015-05-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | http://www.mdpi.com/2072-6694/7/2/0816 |
| _version_ | 1797758807347036160 |
|---|---|
| author | Sacha I. Rothschild |
| author_facet | Sacha I. Rothschild |
| author_sort | Sacha I. Rothschild |
| collection | DOAJ |
| description | Systemic therapy for non-small cell lung cancer (NSCLC) has undergone a dramatic paradigm shift over the past decade. Advances in our understanding of the underlying biology of NSCLC have revealed distinct molecular subtypes. A substantial proportion of NSCLC depends on oncogenic molecular aberrations (so-called “driver mutations”) for their malignant phenotype. Personalized therapy encompasses the strategy of matching these subtypes with effective targeted therapies. EGFR mutations and ALK translocation are the most effectively targeted oncogenes in NSCLC. EGFR mutations and ALK gene rearrangements are successfully being targeted with specific tyrosine kinase inhibitors. The number of molecular subgroups of NSCLC continues to grow. The scope of this review is to discuss recent data on novel molecular targets as ROS1, BRAF, KRAS, HER2, c-MET, RET, PIK3CA, FGFR1 and DDR2. Thereby the review will focus on therapeutic strategies targeting these aberrations. Moreover, the emerging challenge of acquired resistance to initially effective therapies will be discussed. |
| first_indexed | 2024-03-12T18:35:28Z |
| format | Article |
| id | doaj.art-f40690485dfd4287a0c900ca5d02d278 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-12T18:35:28Z |
| publishDate | 2015-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-f40690485dfd4287a0c900ca5d02d2782023-08-02T08:06:29ZengMDPI AGCancers2072-66942015-05-017293094910.3390/cancers7020816cancers7020816Targeted Therapies in Non-Small Cell Lung Cancer—Beyond EGFR and ALKSacha I. Rothschild0Medical Oncology, University Hospital Basel, Petersgraben 4, 4031 Basel, SwitzerlandSystemic therapy for non-small cell lung cancer (NSCLC) has undergone a dramatic paradigm shift over the past decade. Advances in our understanding of the underlying biology of NSCLC have revealed distinct molecular subtypes. A substantial proportion of NSCLC depends on oncogenic molecular aberrations (so-called “driver mutations”) for their malignant phenotype. Personalized therapy encompasses the strategy of matching these subtypes with effective targeted therapies. EGFR mutations and ALK translocation are the most effectively targeted oncogenes in NSCLC. EGFR mutations and ALK gene rearrangements are successfully being targeted with specific tyrosine kinase inhibitors. The number of molecular subgroups of NSCLC continues to grow. The scope of this review is to discuss recent data on novel molecular targets as ROS1, BRAF, KRAS, HER2, c-MET, RET, PIK3CA, FGFR1 and DDR2. Thereby the review will focus on therapeutic strategies targeting these aberrations. Moreover, the emerging challenge of acquired resistance to initially effective therapies will be discussed.http://www.mdpi.com/2072-6694/7/2/0816lung cancertargeted cancer therapyoncogeneROS1c-METRETBRAFHER2FGFR1DDR2 |
| spellingShingle | Sacha I. Rothschild Targeted Therapies in Non-Small Cell Lung Cancer—Beyond EGFR and ALK Cancers lung cancer targeted cancer therapy oncogene ROS1 c-MET RET BRAF HER2 FGFR1 DDR2 |
| title | Targeted Therapies in Non-Small Cell Lung Cancer—Beyond EGFR and ALK |
| title_full | Targeted Therapies in Non-Small Cell Lung Cancer—Beyond EGFR and ALK |
| title_fullStr | Targeted Therapies in Non-Small Cell Lung Cancer—Beyond EGFR and ALK |
| title_full_unstemmed | Targeted Therapies in Non-Small Cell Lung Cancer—Beyond EGFR and ALK |
| title_short | Targeted Therapies in Non-Small Cell Lung Cancer—Beyond EGFR and ALK |
| title_sort | targeted therapies in non small cell lung cancer beyond egfr and alk |
| topic | lung cancer targeted cancer therapy oncogene ROS1 c-MET RET BRAF HER2 FGFR1 DDR2 |
| url | http://www.mdpi.com/2072-6694/7/2/0816 |
| work_keys_str_mv | AT sachairothschild targetedtherapiesinnonsmallcelllungcancerbeyondegfrandalk |